Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. 2017

S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.

BACKGROUND The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is considering switching from biennial guaiac fecal occult blood test (gFOBT) screening between age 50-74 years to the more sensitive, but also less specific fecal immunochemical test (FIT). The aim of this study is to estimate whether the additional benefits of FIT screening compared to gFOBT outweigh the additional costs and harms. METHODS We used microsimulation modeling to estimate quality adjusted life years (QALYs) gained and costs of gFOBT and FIT, compared to no screening, in a cohort of screening participants. We compared strategies with various age ranges, screening intervals, and cut-off levels for FIT. Cost-efficient strategies were determined for various levels of available colonoscopy capacity. RESULTS Compared to no screening, biennial gFOBT screening between age 50-74 years provided 20 QALYs at a cost of CAN$200,900 per 1,000 participants, and required 17 colonoscopies per 1,000 participants per year. FIT screening was more effective and less costly. For the same level of colonoscopy requirement, biennial FIT (with a high cut-off level of 200 ng Hb/ml) between age 50-74 years provided 11 extra QALYs gained while saving CAN$333,300 per 1000 participants, compared to gFOBT. Without restrictions in colonoscopy capacity, FIT (with a low cut-off level of 50 ng Hb/ml) every year between age 45-80 years was the most cost-effective strategy providing 27 extra QALYs gained per 1000 participants, while saving CAN$448,300. CONCLUSIONS Compared to gFOBT screening, switching to FIT at a high cut-off level could increase the health benefits of a CRC screening program without considerably increasing colonoscopy demand.

UI MeSH Term Description Entries
D007120 Immunochemistry Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
D009780 Occult Blood Chemical, spectroscopic, or microscopic detection of extremely small amounts of blood. Fecal Occult Blood Test,Blood, Occult
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006138 Guaiac Resin from wood of certain species of GUAIACUM. It is used as clinical reagent for occult blood.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal

Related Publications

S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
July 2004, Technology Evaluation Center Assessment Program. Executive summary,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
October 1996, Japanese journal of cancer research : Gann,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
March 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
July 2010, Journal of gastroenterology,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
June 1992, British journal of cancer,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
July 2008, Gastroenterology,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
April 2011, International journal of cancer,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
April 2004, The American journal of medicine,
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
May 2019, Cancer prevention research (Philadelphia, Pa.),
S Lucas Goede, and Linda Rabeneck, and Marjolein van Ballegooijen, and Ann G Zauber, and Lawrence F Paszat, and Jeffrey S Hoch, and Jean H E Yong, and Sonja Kroep, and Jill Tinmouth, and Iris Lansdorp-Vogelaar
December 2005, Canadian family physician Medecin de famille canadien,
Copied contents to your clipboard!